EP0845045A1 - Regulation de fonctions cellulaires a l'aide d'une expression ectopique de recepteurs non endogenes de signalisation de cellule - Google Patents

Regulation de fonctions cellulaires a l'aide d'une expression ectopique de recepteurs non endogenes de signalisation de cellule

Info

Publication number
EP0845045A1
EP0845045A1 EP96928135A EP96928135A EP0845045A1 EP 0845045 A1 EP0845045 A1 EP 0845045A1 EP 96928135 A EP96928135 A EP 96928135A EP 96928135 A EP96928135 A EP 96928135A EP 0845045 A1 EP0845045 A1 EP 0845045A1
Authority
EP
European Patent Office
Prior art keywords
receptor
cell
receptors
signalling
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96928135A
Other languages
German (de)
English (en)
Other versions
EP0845045A4 (fr
Inventor
Marvin C. Gershengorn
Erik S. Falck-Pedersen
Ronald G. Crystal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of EP0845045A1 publication Critical patent/EP0845045A1/fr
Publication of EP0845045A4 publication Critical patent/EP0845045A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to expression of a non-endogenous cell signalling receptor in a cell in order to gain control over a cellular function, and more particularly to the transformation of a cell with DNA encoding a non-endogenous cell signalling receptor that utilizes an endogenous signal transduction pathway in the cell, where the receptor can be controllably activated to regulate a cell function controlled by the signal transduction pathway.
  • the differentiated function of a cell is defined, in part, by how it responds to its environment. While any given cell may be exposed to a myriad of signals, the specificity of cellular responses to extracellular regulatory molecules is modulated by the array of receptors present in that cell (1-5) . Interaction of an extracellular regulatory molecule with its cell signalling receptor leads to activation of one or more intracellular signal transduction pathways, eventuating in a response(s) specific for the cell. The specificity of the cellular response is dictated by the specific binding characteristics of the receptor and the specificity of the molecular targets downstream of the signal transduction cascade. In the same cell, a number of different receptors may use the identical signal transduction pathway and thus activation of different receptors can sometimes elicit similar responses (1-5) .
  • the invention provides an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell.
  • the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway.
  • the invention also provides a method of ectopically expressing a non-endogenous receptor in a cell.
  • the method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
  • the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
  • the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
  • the invention further provides a method of regulating a cell function in vivo.
  • the method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
  • the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
  • the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
  • the in vivo cell is then controllably exposed to an extracellular molecule capable of activating the non-endogenous cell signalling receptor, wherein activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function controlled by the endogenous signal transduction pathway.
  • the invention thus provides a method for controlling a cellular function using extracellular molecules which do not normally control the particular cellular function.
  • Various malfunctions of cellular functions due to desensitization of an endogenous cellular receptor, or lack of or mutation of an endogenous cellular receptor, can thereby be overcome using the compositions and methods of the subject invention.
  • Fig. 1 is a Northern analysis of RNA from in vitro primary hepatocytes after incubation with adenovirus vectors, using a mouse TRH-R cDNA probe (lanes 1-6) or a human ⁇ -actin cDNA probe (lanes 7-12) ;
  • Fig. 2 illustrates the binding of methyl- thyrotropin releasing hormone to hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA;
  • Fig. 3 illustrates the TRH stimulation of inositol phosphate formation in hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA
  • Fig. 4 is a Northern analysis of liver RNA with a mouse TRH-R cDNA probe after the animal received the AdCMV.Sgal vector (lane 1) or the AdCMV.mTRH-R vector (lane 2) in vivo;
  • Fig. 5 is a Northern analysis of liver RNA with a ⁇ -actin cDNA probe after the animal received the AdCMV.j ⁇ gal vector (lane 3) or the AdCMV.mTRH-R vector (lane 4) in vivo;
  • Fig. 6 illustrates the binding of methyl- thyrotropin releasing hormone to primary hepatocytes derived from rats following adenovirus-mediated transfer of the TRH-R cDNA in vivo;
  • Fig. 7 illustrates the TRH stimulation of inositol phosphate formation in hepatocytes derived from rats following adenovirus-mediated transfer of the TRH-R cDNA in vivo;
  • Fig. 8 illustrates the modulation of serum glucose by TRH;
  • Fig. 9 illustrates the average change in serum glucose levels.
  • the subject invention provides a recombinant in vivo cell comprising an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell.
  • the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway.
  • the invention also provides a method of ectopically expressing a non-endogenous receptor in a cell.
  • the method comprises selecting a cell for ⁇ transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
  • the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
  • the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
  • the invention further provides a method of regulating a cell function.
  • the method comprises selecting a cell for transformation with DNA encoding a cell signalling receptor not endogenous to the cell.
  • the cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell.
  • the cell is then transformed with DNA encoding the cell signalling receptor, and the DNA is expressed, thereby ectopically expressing the cell signalling receptor in the cell.
  • the cell is then controllably exposed to an extracellular molecule capable of activating the cell signalling receptor, wherein activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function normally controlled by the endogenous signal transduction pathway.
  • the in vivo cell to be transformed can be any suitable cell in which control over a cellular function is desired.
  • the control is accomplished by transforming the cell with DNA encoding a cell signalling receptor not endogenous to the cell, and allowing the non-endogenous receptor to utilize an endogenous signal transduction pathway of the cell.
  • Cellular functions influenced by the signal transduction pathway can thereby be controlled by controlling the activation of the non-endogenous receptor (i.e., by controlled exposure of the non- endogenous receptor to its extracellular signalling molecule) .
  • the subject invention is best understood through a discussion of the various receptors and signal transduction pathways which can be utilized in accordance with the invention.
  • Cells in higher animals normally communicate by means of hundreds of kinds of extracellular signalling molecules, including proteins, small peptides, amino acids, nucleotides, steroids, retinoids, fatty acid derivatives, and even dissolved gases such as nitric oxide and carbon monoxide.
  • signalling molecules relay a "signal" to another cell (a "target cell”) , generally affecting a cellular function.
  • target cell a cell in accordance with the subject invention, such extracellular signalling molecules are controllably administered or provided to a cell in vivo.
  • the cell in vivo has been transformed so that the cell recognizes the extracellular signalling molecule via a non-endogenous receptor expressed by the cell.
  • the non-endogenous receptor is specific for and binds the extracellular signalling molecule, and the presence of the non-endogenous receptor allows the in vivo cell to recognize the extracellular signalling molecule that it would not have recognized but for the presence of the non-endogenous receptor.
  • the binding of the non-endogenous receptor to the extracellular signalling molecule then initiates a response in the transformed cell.
  • these receptors for extracellular signalling molecules are collectively referred to as "cell signalling receptors”.
  • cell signalling receptors are transmembrane proteins on the transformed cell surface; when they bind an extracellular signalling molecule (a ligand) , they become activated so as to generate a cascade of intracellular signals that alter the behavior of the cell.
  • these receptors are collectively referred to as "cell surface signalling receptors”.
  • the receptors are inside the transformed cell and the signalling ligand has to enter the cell to activate them; these signalling molecules therefore must be sufficiently small and hydrophobic to diffuse across the plasma membrane of the cell.
  • these receptors are collectively referred to as "intracellular cell signalling receptors”.
  • Cell surface signalling receptors generally include three classes, defined by the transduction mechanism used. These are ion channel linked receptors, guanine nucleotide binding protein linked receptors, and enzyme linked receptors.
  • Ion channel linked receptors also known as transmitter-gated ion channels, are involved in rapid synaptic signalling between electrically excitable cells. This type is signalling is mediated by a small number of extracellular signalling molecules known as neurotransmitters that transiently open or close the ion channel formed by the receptor protein to which they bind.
  • the ion channel linked receptors belong to a family of homologous, multipass transmembrane proteins, and include ion channels for sodium, potassium, calcium, and chloride ions.
  • Ion channels are not continuously open. Instead they have "gates", which open briefly and then close again. In most cases the gates open in response to a specific stimulus, such as the binding of a ligand (ligand-gated channels) .
  • the ligand can be either an extracellular signalling molecule, specifically a neurotransmitter (transmitter-gated channels) , or an intracellular molecule, such as an ion (ion-gated channels) or a nucleotide (nucleotide-gated channels) .
  • the second class of cell surface receptor proteins is the guanine nucleotide binding protein linked receptors. These receptors are also known as G protein linked receptors. These receptors act indirectly to regulate the activity of a separate plasma-membrane-bound target protein, which can be an enzyme or an ion channel. The interaction between the receptor and the target protein is mediated by a third protein, called a trimeric GTP-binding regulatory protein (G protein) .
  • G protein GTP-binding regulatory protein
  • the activation of the target protein either alters the concentration of one or more intracellular mediators (if the target protein is an enzyme) or alters the ion permeability of the plasma membrane (if the target protein is an ion channel) .
  • the intracellular mediators act in turn to alter the behavior of yet other proteins in the cell. All of the G-protein-linked receptors belong to a large superfamily of homologous, seven-pass transmembrane proteins.
  • G protein linked receptors are the largest family of cell surface receptors. More than 100 members have already been defined in mammals. G protein linked receptors mediate the cellular responses to an enormous diversity of signalling molecules, including hormones, neurotransmitters, and local mediators, which are as varied in structure as they are in function: the list includes proteins and small peptides, as well as amino acid and fatty acid derivatives. The same ligand can activate many different family members. At least 9 distinct G protein linked receptors are activated by adrenaline, for example, another 5 or more by acetylcholine, and at least 15 by serotonin.
  • G protein linked receptors include, for example, the alpha-adrenergic receptors, the beta-adrenergic receptors, dopaminergic receptors, serotonergic receptors, muscarinic cholinergic receptors, peptidergic receptors, and the thyrotropin releasing hormone receptor.
  • G protein linked receptors activate a chain of events that alters the concentration of one or more small intracellular signalling molecules. These small molecules, often referred to as intracellular mediators (also called intracellular messengers or second messengers) , in turn pass the signal on by altering the behavior of selected cellular proteins.
  • intracellular mediators also called intracellular messengers or second messengers
  • cAMP cyclic AMP
  • Ca 2+ changes in the concentrations are stimulated by distinct pathways in most animal cells, and most G-protein-linked receptors regulate one or the other of them.
  • the third type of cell surface receptor proteins are the enzyme linked receptors which, when activated, either function directly as enzymes or are associated with enzymes. Most are single-pass transmembrane proteins, with their ligand-binding site outside the cell and their catalytic site inside. Compared with the other two classes, enzyme linked receptors are heterogeneous, although the great majority are protein kinases, or are associated with protein kinases, that phosphorylate specific sets of proteins in the target cell.
  • transmembrane guanylyl cyclases which generate cyclic GMP directly
  • receptor tyrosine phosphatases which remove phosphate from phosphotyrosine side chains of specific proteins
  • transmembrane receptor serine/threonine kinases which add a phosphate group to serine and threonine side chains on target proteins
  • receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
  • receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
  • receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
  • receptor tyrosine kinases which add a phosphate group to serine and threonine side chains on target proteins
  • receptor tyrosine kinases which add a phosphate group to serine and th
  • receptors The last two types of receptors are by far the most numerous, and they are thought to work in a similar way: ligand binding usually induces the receptors to dimerize, which activates the kinase activity of either the receptor or its associated nonreceptor tyrosine kinase. When activated, receptor tyrosine kinases usually cross-phosphorylate themselves on multiple tyrosine residues, which then serve as docking sites for a small set of intracellular signaling proteins. In this way, a multiprotein signalling complex is activated from which the signal spreads to the cell interior.
  • cell signalling is also accomplished via intracellular cell signalling receptors. As indicated above, these receptors are inside the target cell and the signalling ligand has to enter the cell to activate them.
  • Steroid hormones, thyroid hormones, retinoids, and vitamin D are examples of small hydrophobic molecules that differ greatly from one another in both chemical structure and function.
  • Steroid hormone receptors include progesterone receptors, estrogen receptors, androgen receptors, glucocorticoid receptors, and mineralocorticoid receptors.
  • Thyroid hormone receptors include the thyroid stimulating hormone receptor.
  • Retinoid receptors include the receptor for retinoic acid.
  • a cell is transformed with DNA encoding one or more of these cell signalling receptors which is not endogenous to the cell (which may be a cell surface signalling receptor or an intracellular cell signalling receptor) .
  • the non-endogenous receptor is capable of activating a signal transduction pathway that is endogenous to the cell.
  • a "non-endogenous" receptor is a receptor not normally present in/on (used interchangeably throughout this application) the particular cell. A receptor, therefore, may be non- endogenous to the transformed cell even though the receptor is present in/on other cells in the selected organism (i.e. in a human being) .
  • a receptor present only in heart muscle tissue is a "non- endogenous" receptor in a liver cell.
  • an "endogenous” pathway as used herein refers to a signal transduction pathway that is normally present in the transformed cell.
  • ectopic expression as used herein refers to expression of a receptor in/on a particular cell in/on which the receptor is not normally present.
  • “Eutopic” expression in contrast, is expression of a receptor in/on a particular cell in/on which the receptor is normally present.
  • the DNA encoding the no -endogenous receptor is capable of activating an endogenous signal transduction pathway in the transformed cell.
  • Signal transduction pathways are numerous, and include, for example, adenylate cyclase pathways, guanylate cyclase pathways, phosphoinositol turnover pathways, tyrosine kinase pathways, ion channel pathways, and calcium ion pathways.
  • the initial signal produced by the binding of an extracellular signalling molecule to a cell signalling receptor is transduced intracellularly via a signal transduction pathway that may be multiple and interactive.
  • Signal transduction pathways involve cAMP, cGMP, arachidonic acid, inositol 1,4,5-tris-phosphate (IP 3 ) , Ca 2+ , and other ions as second messengers and are produced by enzymes (such as adenylate and guanylate cyclases and phospholipases A 2 and C) and ion channels.
  • enzymes such as adenylate and guanylate cyclases and phospholipases A 2 and C
  • an extracellular molecule-receptor complex does not interface directly with these effectors but acts via an intermediate modulating signal transducer, often a G protein.
  • cAMP is the prototypical second messenger. Intracellular levels of cAMP are determined, in large part, by ligand-receptor interactions. This physiological event involves the interaction of three cellular components located near the plasma membrane: the ligand receptor, a signal transducer (G protein) , and the effector enzyme (adenylate cyclase) .
  • Cyclic AMP is a second messenger for many hormones, including epinephrine, glucagon, norepinephrine, parathyroid and luteinizing hormones, and thyroid-stimulating and melanocyte-stimulating hormones.
  • Cyclic AMP affects a wide range of cellular processes: increases lipolysis, glycogen degradation, gluconeogenesis, ketogenesis, ion permeability of epithelia, renin production by kidney, contraction of cardiac muscle, HCl secretion by the gastric mucosa, amylase release by the parotid gland, dispersion of melanin granules, and insulin release by the pancreas; decreases aggregation of platelets, and growth of tumor cells in tissue culture.
  • the activation of adenyl cyclase leads to an increased amount of cyclic AMP inside the cell. Cyclic AMP then activates a protein kinase, which phosphorylates one or more proteins.
  • glycogen synthetase and phosphorylase kinase results in decreased synthesis and enhanced degradation of glycogen.
  • Table 1 classifies various hormone receptors and effectors according to the pathway utilized. Several receptors contain an intrinsic hormone-activated tyrosine kinase activity.
  • Guanylate cyclase catalyzes the formation of cGMP from GTP, in analogy with adenylate cyclase. Guanylate cyclase, however, exists in cells in both soluble and membrane-associated forms. The membrane- associated form is regulated by hormones and other ligands. Like the tyrosine kinases and unlike adenylate cyclase, guanylate cyclase may directly serve receptor and effector functions.
  • a number of hormones and ligands mediate their cellular actions via calcium ions and DAG as second messengers.
  • the second messengers modulate the activity of protein kinases regulated by calcium binding-regulatory protein (e.g. calmodulin) , and DAG activates protein kinase C.
  • calmodulin calcium binding-regulatory protein
  • DAG activates protein kinase C.
  • These enzymes phosphorylate specific intracellular proteins, which results in further hormone action.
  • Example of hormones using this signaling system in specific tissues include alpha-1-adrenergic and muscarinic cholinergic agents, vasopressin, histamine, cholecystokinin, LHRH, thyrotropin-releasing hormone, angiotensin II, and oxytocin.
  • the various hormone ligands that stimulate phosphoinositide turnover interact with the receptors that activate G proteins, as described for adenylate cyclase. These activated G proteins, however, are coupled to stimulation of phospholipase C activity.
  • thyroid-stimulating hormone TSH
  • ACTH adrenocorticotropic hormone
  • LH luteinizing hormone
  • Atrial peptide also called atrial natriuretic factor
  • Insulin-like growth factor somatomedin-C
  • Phosphoinosi ol Turnover and Calcium Flux ' Acetylcholine receptor (muscarinic) Alpha-adrenergic catecholamines Angiotensin Luteinizing hormone-releasing hormone Vasopressin Thyrotropin-releasing hormone
  • a method for transforming cells must also be selected.
  • Various methods are known in the art.
  • One of the first methods was microinjection, in which DNA was injected directly into the nucleus of cells through fine glass needles. This was an efficient process on a per cell basis, that is, a large fraction of the injected cells actually got the DNA, but only a few hundred cells could be injected in a single experiment.
  • the earliest method for introducing DNA into cells en masse was to incubate the DNA with an inert carbohydrate polymer (dextran) to which a positively charged chemical group (DEAE, for diethylaminoethyl) had been coupled.
  • the DNA sticks to the DEAE-dextran via its negatively charged phosphate groups.
  • These large DNA-containing particles stick in turn to the surfaces of cells, which are thought to take them in by a process known as endocytosis.
  • Some of the DNA evades destruction in the cytoplasm of the cell and escapes to the nucleus, where it can be transcribed into RNA like any other gene in the cell.
  • the DEAE-dextran method while relatively simple, was very inefficient for many types of cells, so it was not a reliable method for the routine assay of the biological activity of a purified DNA preparation.
  • the breakthrough that eventually made gene transfer a routine tool for workers studying mammalian cells was the discovery that cells efficiently took in DNA in the form of a precipitate with calcium phosphate. With this new method, the yield of virus from cells transfected with viral DNA was a hundred times greater than with the DEAE-dextran method.
  • Biological markers can be used to identify the cells carrying recombinant DNA molecules. In bacteria, these are commonly drug-resistance genes. Drug resistance is used to select bacteria that have taken up cloned DNA from the much larger population of bacteria that have not.
  • the transfer of exogenous DNA into cells was detected because the DNA had a biological activity, it led to production of infectious virus or produced stable changes in the growth properties of the transfected cells.
  • the DNA tumor virus herpes simplex virus (HSV) , contained a gene encoding the enzyme thymidine kinase (the tk gene) .
  • the HSV tk gene can be used as a selectable genetic marker in mammalian cells in much the same way that drug-resistance genes worked in bacteria, to allow rare transfected cells to grow up out of a much larger population that did not take up any DNA.
  • the cells are transferred to selective growth medium, which permits growth only of cells that took up a functional tk gene (and the transferred DNA of interest) .
  • Various dominant selectable markers are now known in the art, including: aminoglycoside phosphotransferase (APH) , using the drug G418 for selection which inhibits protein synthesis; the APH inactivates G418; dihydrofolate reductase (DHFR) :Mtx-resistant variant, using the drug methotrexate (Mtx) for selection which inhibits DHFR; the variant DHFR is resistant to Mtx; hygromycin-B-phosphotransferase (HPH) , using the drug hygromycin-B which inhibits protein synthesis; the HPH inactivates hygromycin B; thymidine kinase (TK) , using the drug aminopterin which inhibits de novo purine and thymidylate synthesis; the TK synthesizes thymidylate; xanthine-guanine phosphoribosyltransferase (XGPRT) , using the drug mycophenolic
  • Gene amplification can also be used to obtain very high levels of expression of transfected gene.
  • Mtx an inhibitor of a critical metabolic enzyme, DHFR
  • DHFR a critical metabolic enzyme that kills cells.
  • a gene to be expressed in cells is cotransfected with a cloned dhfr gene, and the transfected cells are subjected to selection with a low concentration of Mtx. Resistant cells that have taken up the dhfr gene (and, in most cases, the cotransfected gene) multiply. Increasing the concentration of Mtx in the growth medium in small steps generates populations of cells that have progressively amplified the dhfr gene, together with linked DNA.
  • DNA can also be incorporated into artificial lipid vesicles, liposomes, which fuse with the cell membrane, delivering their contents directly into the cytoplasm.
  • Microinjection the surest way to get DNA into cells, can now be performed with a computer- assisted apparatus that increases by 10-fold or more the number of cells that can be injected in one experiment.
  • DNA is absorbed to the surface of tungsten microprojectiles and fired into cells with a device resembling a shotgun.
  • naked DNA introduced by transfection can be transiently expressed in up to half the cells in a culture, more frequently the fraction of transiently transfected cells is much lower. In fact, some cells are almost completely refractory to transfection by the artificial methods described above.
  • Many applications of recombinant DNA technology require introducing foreign genes (i.e. non-endogenous receptors) into recalcitrant cell types.
  • Potential gene therapy strategies for example, require efficient means for transferring genes into normal human cells.
  • viruses Viral growth depends on the ability to get the viral genome into cells, and viruses have devised clever and efficient methods for doing it. The earliest viral vectors, based on the monkey tumor virus SV40, simply substituted some of the viral genes with the foreign gene.
  • recombinant molecules prepared as bacterial plasmids, were transfected into monkey cells together with a second plasmid that supplied the missing viral genes.
  • viral gene products produced from the two plasmids cooperate to replicate both plasmids and package each into virus particles.
  • the virus stock that emerges from the cell is a mixture of two viruses, each of which is by itself defective (that is, it cannot replicate on its own because it is missing necessary viral genes) . Nevertheless, this virus stock can then be used to infect new cells, efficiently introducing and expressing the foreign gene in the recipient cells.
  • a hybrid method that uses transfection to get DNA into cells and a viral protein to replicate it once inside is now commonly used for high-level production of protein from a cloned gene.
  • This procedure uses a cell line, COS cells, carrying a stably integrated portion of the SV40 genome. These cells produce the viral T antigen protein, which triggers replication of viral DNA by binding to a DNA sequence termed the origin of replication.
  • the foreign gene to be expressed is cloned into a plasmid that carries the SV40 origin of replication. After transfection into COS cells, the plasmid is replicated to a very high number of copies, increasing the expression level of the foreign gene.
  • SV-40-based viral vectors are limited for a number of reasons: they infect only monkey cells, the size of foreign gene that can be inserted is small, and the genomes are often rearranged or deleted. Other viral vectors are more commonly used now, either because they can infect a wider range of cells or because they accept a wider range of foreign genes.
  • Vaccinia virus is a large DNA-containing virus that replicates entirely in the cytoplasm. Early vaccinia vectors incorporated the foreign gene directly into a nonessential region of the viral genome. Recombinant viruses are viable and upon infection transcribe the foreign gene from a nearby viral promoter.
  • a more versatile vaccinia expression system uses a ready-made recombinant virus that expresses a bacteriophage RNA polymerase.
  • the gene to be expressed is simply cloned into a plasmid carrying a bacteriophage promoter.
  • the plasmid is transfected into cells that have been previously infected with the vaccinia virus that expresses the RNA polymerase.
  • the gene on the plasmid is efficiently transcribed by the bacteriophage polymerase, accounting for up to 30 percent of the RNA in the cell.
  • An additional feature of vaccinia virus infection is that the virus shuts down host cell protein synthesis so that viral mRNA (and mRNA from the plasmid) are preferentially translated into protein.
  • Baculovirus Another virus widely used for protein production is an insect virus, baculovirus.
  • Baculovirus attracted the attention of researchers because during infection, it produces one of its structural proteins (the coat protein) to spectacular levels. If a foreign gene were to be substituted for this viral gene, it too ought to be produced at high levels.
  • Baculovirus like vaccinia, is very large, and therefore foreign genes must be placed in the viral genome by recombination.
  • the gene of interest is cloned in place of the viral coat protein gene in a plasmid carrying a small portion of the viral genome. The recombinant plasmid is cotransfected into insect cells with wild- type baculovirus DNA.
  • the plasmid and viral DNAs recombine through homologous sequences, resulting in the insertion of the foreign gene into the viral genome.
  • Virus plaques develop, and the plaques containing recombinant virus look different because they lack the coat protein.
  • the plaques with recombinant virus are picked and expanded. This virus stock is then used to infect a fresh culture of insect cells, resulting in high expression of the foreign protein.
  • baculovirus vectors see reference (51) .
  • Retroviruses are RNA viruses with a life cycle quite different from that of the lytic viruses. When they infect cells, their RNA genomes are converted to a DNA form (by the viral enzyme reverse transcriptase) . The viral DNA is efficiently integrated into the host genome, where it permanently resides, replicating along with host DNA at each cell division. This integrated provirus steadily produces viral RNA from a strong promoter located at the end of the genome (in a sequence called the long terminal repeat or LTR) .
  • LTR long terminal repeat
  • This viral RNA serves both as mRNA for the production of viral proteins and as genomic RNA for new viruses. Viruses are assembled in the cytoplasm and bud from the cell membrane, usually with little effect on the cell's health. Thus, the retrovirus genome becomes a permanent part of the host cell genome, and any foreign gene placed in a retrovirus ought to be expressed in the cells indefinitely.
  • Retroviruses are therefore attractive vectors because they can permanently express a foreign gene in cells. Moreover, they can infect virtually every type of mammalian cell, making them exceptionally versatile. Because of their versatility, retroviruses are also the vector of choice for gene therapy. In the design and use of retroviral vectors, the vectors usually contain a selectable marker as well as the foreign gene to be expressed. Most of the viral structural genes are gone, so these vectors cannot replicate as viruses on their own. To prepare virus stocks, cloned proviral DNA is transfected into a packaging cell. These cells usually contain an integrated provirus with all its genes intact, but lacking the sequence recognized by the packaging apparatus.
  • the packaging provirus produces all the proteins required for packaging of viral RNA into infectious virus particles but it cannot package its own RNA. Instead, RNA transcribed from the transfected vector is packaged into infectious virus particles and released from the cell. The resulting virus stock is termed helper-free because it lacks wild-type replication-competent virus. This virus stock can be used to infect a target cell culture.
  • the recombinant genome is efficiently introduced, reverse- transcribed into DNA (by reverse transcriptase deposited in the virus by the packaging cells) , and integrated into the genome.
  • the cells now express the new virally introduced gene, but they never produce any virus, because the recombinant virus genome lacks the necessary viral genes.
  • retrovirus vectors see references (52,53).
  • Another viral vector is adenovirus, reviewed by Berkner, K.L. (54) .
  • Still another viral vector is herpesvirus.
  • U.S. Patent No. 4,237,224 to Cohen and Boyer describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including procaryotic organisms and eucaryotic cells grown in tissue culture. The DNA sequences are cloned into the plasmid vector using standard cloning procedures in the art, as described by Maniatis et al. , Molecular Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, New York (1982) .
  • a transformed cell containing a foreign gene of interest i.e., a non-endogenous receptor
  • the cell may be transformed in vitro and reinserted into a multicellular organism, or the cell may be transformed in vivo.
  • a retrovirus acts as a vector to carry a gene into a cell, so the cell can be regarded as a vector for carrying the gene into a patient's body.
  • Suitable cells for transformation and use in gene therapy should be readily obtainable, grow well in culture, and be able to withstand the various manipulations involved in, for example, retrovirus or adenovirus infection.
  • vector cells should be easy to return to the patient after such transformation and should continue to live for many months, preferably for the life of the patient. See Friedmann (55), Verma (56), Anderson (62) and Mulligan (63) for discussions of gene therapy.
  • the cells of the bone marrow have many of these desirable features.
  • the bone marrow contains stem cells that give rise to all cells of the hematopoietic series. Infection of these stem cells results in a continuous supply of cells containing the therapeutic gene.
  • the techniques for reconstituting the bone marrow of patients and experimental animals are well worked out. Convincing evidence that genes introduced in hematopoietic stem cells are expressed and that they can produce a therapeutic effect has come from experiments with a mutant dihydrofolate reductase gene (DHFR) . See Corey et al. (57) .
  • Another cell type that has been studied intensively as a vehicle for gene transfer is the skin fibroblast. Fibroblasts are easily obtainable, grow well in culture, and have been the subjects of many experiments, and skin fibroblasts can be efficiently infected with viral vectors, such as retroviral vectors. See Palmer et al. (58).
  • liver Another target tissue for gene therapy is the liver.
  • Techniques have been developed for isolating and culturing hepatocytes, so the appropriate target cells are available for viral-mediated gene transfer. See Anderson et al. (59).
  • suitable cells to be transformed according to the subject invention include, for example, a liver cell (known as a hepatocyte) in which one desires to control glycogenolysis.
  • a liver cell known as a hepatocyte
  • This can be accomplished by transforming the liver cell with DNA encoding a cell signalling receptor not endogenous to the cell (i.e. not normally present on the liver cell), where the receptor is capable of activating a signal transduction pathway endogenous (i.e. normally present in the cell) to the liver cell.
  • the non-endogenous receptor is chosen such that the compatible signal transduction pathway regulates glycogenolysis in the cell.
  • the cAMP pathway and phosphoinositide pathways within the liver cell regulate glycogenolysis, and DNA encoding a thyrotropin releasing hormone receptor (a receptor not endogenous to the liver cell) can be transformed into the liver cell to activate these two endogenous pathways, thereby providing for controllable activation of the pathways (by introducing an extracellular molecule capable of binding to the non-endogenous receptor and thereby stimulating the endogenous pathway) .
  • a liver cell is one example of a suitable in vivo cell according to the subject invention.
  • Other cells are equally transformable, such as cells of the pulmonary airways. These cells can be transformed with a thyroid-stimulating hormone receptor which can utilize the pulmonary airways' endogenous cyclic AMP signal transduction pathway. Extracellular molecules capable of activating the thyroid-stimulating hormone receptor would therefore control the same cellular function as do adrenergic agonists and bronchodilating drugs (which utilize the cAMP pathway to normally control cellular function) .
  • Adenovirus-based vectors to transform liver cells.
  • Adenovirus based vectors have been used successfully to express a number of mammalian and viral proteins but they have not been used to ectopically express cell signalling receptors in vivo .
  • the following examples show that functions of a specific cell type can be regulated in an intact animal by an agonist that does not usually affect functions in this cell type (because the cell does not endogenously express the receptor for this agonist) when the receptor for this agonist is expressed by adenovirus-mediated gene transfer. This is so because the expressed non-endogenous receptor couples to an endogenous signal transduction pathway and thereby regulates cell function.
  • TRH neurohormone thyrotropin-releasing hormone
  • This invention has important therapeutic applications. These applications include temporary relief of life-threatening illnesses, with receptor expression in diseased tissues and in tissues unaffected by the disease process.
  • An example of an application in a diseased tissue would be the expression of the receptor for thyroid-stimulating hormone in pulmonary airways to mediate, via an elevation of cyclic AMP, which is the same pathway used by adrenergic agonists and bronchodilating drugs, a bronchodilatory response in patients with chronic obstructive pulmonary disease or asthma suffering a marked exacerbation.
  • a therapeutic advantage of using more than one receptor to mediate the desired response is that the efficacy of most drugs decreases upon repeated administrations, a process termed tachyphylaxis, which is usually caused by receptor desensitization.
  • tachyphylaxis which is usually caused by receptor desensitization.
  • Another application is for the treatment of diseases for which regulation of a physiologic function in a healthy organ would counter-balance the effects of a disease process.
  • An example of this is presented in the Examples which follow, in which blood glucose was elevated by TRH after etopic expression of TRH receptors in liver.
  • This approach can be used in a patient with severe hypoglycemia who harbors an inoperable insulin-secreting tumor (insulinoma) to maintain normoglycemia over an extended period of time.
  • glycogenolysis Maintenance of blood glucose by glycogenolysis in the liver is normally initiated by extracellular regulatory molecules such as glucagon and vasopressin triggering specific receptors on hepatocytes to activate the cAMP or phosphoinositide signal transduction pathways.
  • the subject invention demonstrates that the normal ligand-receptor regulators of glycogenolysis can be bypassed using an adenovirus vector to ectopically express the non-endogenous mouse pituitary thyrotropin releasing hormone receptor
  • TRH-R cDNA in rat liver in vivo.
  • the ectopically expressed TRH-R links to the phosphoinositide pathway, providing a means to activate glycogenolysis with TRH, an extracellular ligand not normally associated with liver physiology.
  • TRH is administered to these animals, the phosphoinositide path is activated resulting in a sustained rise in blood glucose.
  • the invention provides an approach to the therapy of such disorders which is to bypass the normal extracellular regulatory molecule and its specific endogenous receptor by using an alternative ligand and non-endogenous receptor to trigger the relevant endogenous signal transduction pathway.
  • Such a strategy can be used to correct abnormalities of extracellular regulatory molecules or their specific endogenous receptors, as well as to modulate specific physiologic functions in disease states by re-establishing control of specific signal transduction pathways.
  • the subject invention provides a new strategy to specifically control the differentiated function of cells in vivo by providing the means to trigger a specific signal transduction pathway by using a gene transfer vector to ectopically express a naturally occurring receptor in cells of an organ that do not normally express that receptor (i.e. a non-endogenous receptor) .
  • the expressed receptor links to its natural signal transduction pathway, enabling specific responses to be triggered in the target cells by a ligand relevant for that receptor.
  • TRH thyrotropin- releasing hormone
  • TRH-R thyrotropin- releasing hormone receptor
  • TRH-Rs in pituitary cells are stimulated by TRH
  • the TRH-R triggers, via a guanine nucleotide binding protein, the phosphoinositide-calcium-protein kinase C signal transduction pathway and the pituitary releases thyroid stimulating hormone (TSH) (2,13,14).
  • TSH thyroid stimulating hormone
  • triggering of the phosphoinositide pathway in hepatocytes results not in TSH release, but in glycogen breakdown and the release of glucose into the circulation (5) .
  • the subject invention provides for the transfer and expression of the TRH-R cDNA in hepatocytes in vivo with linkage of the expressed receptor to the hepatocyte phosphoinositide pathway. Therefore, systemic administration of TRH to animals expressing TRH receptors in the liver triggers the phosphoinositide pathway in hepatocytes, resulting in a rise in blood glucose.
  • the parent plasmid, pAdCMV.mTRH-R was constructed by inserting a 1.2 kb JScoRI-Notl fragment containing the protein-coding region of the mouse TRH-R cDNA, nucleotides 233-1462 of plasmid pBSmTRHR (43) , into plasmid pGEM2-L3-114 at the EcoRI-BamHl site.
  • Hindlll linkers were ligated and a 1.4 kb Hindlll fragment containing mouse TRH-R cDNA and the adenovirus E2 poly(A) signal sequence was isolated and inserted into the Hindlll site of the pAdCMV-HS-Vector which contains the left end replication and packaging elements of adenovirus, the cytomegalovirus-1 promoter and splicing elements from plasmid pML-IS Cat (44) .
  • the virus AdCMV.mTRH-R was constructed by overlap recombination as described by Tantravahi et al . (45) . All transfections were carried out in human embryonic kidney cells transformed with the El region of adenovirus type 5 according to the procedure of Graham et al. (46). Following plaque purification, virus was grown in 293 cells in suspension cultures as described by Tantravahi et al. (45). The entire sequence coding for the adenovirus Ela gene was removed as well as the 5' 1.8 kb of the Elb gene. Co-transfection of pAdCMV.mTRH-R with the large fragment of adenovirus (3.8-100 map units) into 293 cells resulted in production of recombinant virus AdCMVmTRHR.
  • pAdCMV.mTRH-R The construction of the recombinant plasmid designated pAdCMV.mTRH-R and the adenovirus vector designated AdCMV.mTHR-R is described fully by Gershengorn et al. (10) and Falck-Pedersen et al. (30).
  • AdCMV.mTRH-R The ability of AdCMV.mTRH-R to transfer and express the mouse TRH-R cDNA in rat hepatocytes was first demonstrated in vi tro.
  • the replication-deficient recombinant adenovirus vectors are all Ela " , partial Elb", partial E3 " based on adenovirus type 5, in which an expression cassette containing a promoter, driving the expression of a recombinant gene, is inserted at the site of the El deletion.
  • AdCMV.mTRH-R contains an expression cassette with the cytomegalovirus early intermediate promoter/enhancer (CMV) followed by the mouse thyrotropin releasing hormone receptor (TRH-R) cDNA (30) .
  • CMV cytomegalovirus early intermediate promoter/enhancer
  • TRH-R mouse thyrotropin releasing hormone receptor
  • AdCMV.j ⁇ gal carries the CMV promoter and the E. coli LacZ gene [encoding ⁇ -galactosidase ( ⁇ gal)] (31) .
  • the adenovirus vectors were prepared, purified, and titered as previously described (32,33).
  • Primary hepatocyte cultures established from 250-300 g male Sprague-Dawley rats (19) , were exposed to AdCMV.mTRH-R at different multiplicity of infection (moi, 1, 10, 50, 100) ; uninfected cells and cells infected with AdCMV.j ⁇ gal (moi 50) were used as controls.
  • RNA (10 ⁇ g/lane) from primary hepatocytes was evaluated 24 hr after incubation with the vectors using a mouse
  • TRH-R cDNA probe (lanes 1-6) , or as a positive control, human ⁇ -actin cDNA probe (lanes 7-12) .
  • the sizes of the transcripts are indicated.
  • Incubation of the hepatocytes with AdCMV.mTRH-R resulted in a dose-dependent expression of TRH-R mRNA transcripts
  • hepatocytes that were uninfected or infected with the control vector AdCMV.j ⁇ gal demonstrated no TRH-R mRNA transcripts (see Fig. 1, lanes 1 and 2) , although control ⁇ -actin mRNA transcripts were similar in all samples (see Fig. 1, lanes 7-12) .
  • Fig. 2 illustrates the binding of methyl- thyrotropin releasing hormone (methyl-TRH) to hepatocytes following adenovirus-mediated in vitro transfer of the TRH-R cDNA.
  • methyl-TRH methyl- thyrotropin releasing hormone
  • the hepatocytes (10 6 /well) were incubated for 60 min with [ 3 H]methyl-TRH (82.5 Ci/mmol, New England Nuclear-Dupont, Boston, MA) or [ 3 H]methyl-TRH plus excess unlabeled methyl-TRH (Sigma, St. Louis, MO) .
  • Free ligand was removed by aspirating the medium and washing the cells 5 times with 2 ml (4°C) Hanks balanced salt solution. Cell associated radioactivity was measured by dissolving the cells with 1 ml of 0.4 N NaOH and counting.
  • Fig. 3 shows the TRH stimulation of inositol phosphate formation in hepatocytes following adenovirus-mediated in vi tro transfer of the TRH-R cDNA.
  • Primary hepatocytes were exposed to the vectors AdCMV. ⁇ gal or AdCMV.mTRH-R. After 24 hr, the cells were labeled for 24 hr with myo- [ 3 H] inositol (myo- [2-
  • inositol 20 Ci/mmol, Amersham Corporation, Arlington Heights, IL
  • incubated 5 min, 37°C
  • 10 mM LiCl stimulated (60 min, 37°C) with methyl-TRH.
  • the cells were then lysed, the inositol phosphates were separated by anion-exchange chromatography and the radioactivity counted.
  • the fold stimulation of inositol phosphates formation was calculated as: (dpm in inositol phosphates x 100/dpm in lipids of stimulated cells) - (dpm in inositol phosphates x 100/dpm in lipids of unstimulated cells) (35) .
  • triplicate measurements were made in hepatocytes from two different animals.
  • the AdCMV.mTRH-R vector effectively transferred the TRH-R cDNA to the rat liver in vivo, with the consequent ectopic expression of functional TRH-Rs in the hepatocytes.
  • the AdCMV.mTRH-R was administered intravenously to the animals, a route of administration of replication deficient adenovirus vectors that results in > 90% detected expression of the exogenous gene in hepatocytes (16) .
  • AdCMV.mTRH-R AdCMV.j ⁇ gal
  • AdCMV.Null the "Null" vector is 'similar to the other vectors except that the expression cassette contains the CMV promoter but no recombinant gene) (31)] were administered via the right external jugular vein (5xl0 9 pfu, 100 ⁇ l 0.9% NaCl). The livers were recovered 5 days later.
  • Figs. 4 and 5 are Northern analyses. Liver RNA (10 ⁇ g/lane) was evaluated with a mouse TRH-R cDNA probe (Fig. 4, lanes 1 and 2) or, as a positive control, ⁇ -actin cDNA (Fig. 5, lanes 3 and 4) . The sizes of the transcripts are indicated. Lanes 1 and 3 (Fig. 4 and Fig. 5, respectively) are animals receiving AdCMV./Sgal. Lanes 2 and 4 (Fig. 4 and Fig.
  • hepatocytes recovered from animals receiving AdCMV.mTRH-R in vivo demonstrated high levels of methyl-TRH specific binding, whereas no specific methyl-TRH binding was observed in naive animals or animals receiving the control vector AdCMV.j ⁇ gal (Fig. 6) .
  • the analysis of [ 3 H]methyl-TRH binding was identical to that described for Fig. 2. Triplicate measurements were made from three individual animals per condition.
  • the hepatocytes derived from the AdCMV.mTRH-R infected animals demonstrated 6.lxlO 5 TRH-R receptors/cells, with a Kd of 2.51 ⁇ 0.32 nM.
  • the methyl-TRH complex underwent internalization in hepatocytes from AdCMV.mTRH-R infected animals (not shown) .
  • the liver maintains blood glucose levels by secreting glucose derived from hepatocyte glycogen stores into the circulation. This process is regulated by specific cell-surface receptors activating either of two signal transduction pathways, the cAMP pathway or the phosphoinositide pathway. Both converge to activate phosphorylase B which cleaves glycogen to glucose-1-phosphate, which is then isomerized to glucose-6-phosphate by phosphoglucomutase, and finally dephosphorylated by glucose-6-phosphatase to glucose which is secreted (17) .
  • This example discloses the modulation in levels of serum glucose by TRH in animals following in vivo transfer of the TRH-R cDNA to the liver.
  • the vectors AdCMV.mTRH-R or AdCMV.Null (5xl0 9 pfu) , or saline (0.9%) as negative control (all in 100 ⁇ l) were administered to rats as described above.
  • the animals were anaesthetized by methoxyflurane (Pitman-Moore, Mundelein, IL) inhalation and the left and right external jugular veins were cannulated. After 15 min to permit stabilization, a 15 min baseline period was started, during which serum samples for glucose levels were obtained every 5 min.
  • methyl-TRH 500 ⁇ g in 100 ⁇ l or saline (0.9%, 100 ⁇ l) was administered in one cannula and the serum samples obtained from the other cannula every 5 min for 55 min. Serum glucose levels were determined by colormetric assay (Sigma Diagnostics, St. Louis, MO).
  • Fig. 8 illustrates the modulation of serum glucose by TRH.
  • the baseline glucose levels were determined for each animal as an average from -15 to 0 before administration of methyl-TRH or saline.
  • the data are presented as the absolute change from the average baseline serum glucose level (mM) using each individual animal as its own control, and averaging the values at each time point for each group of animals.
  • the data is presented as the mean for all animals in the group at each time point.
  • the normal range for serum glucose Sprague-Dawley rats is 2.5 - 6.7 mM(36) .
  • the average baseline values were: AdCMV.mTRH-R(IV) /TRH group 6.1 ⁇ 0.8 mM; AdCMV.mTRH-R(IP)/TRH group 5.6 ⁇ 0.5 mM; AdCMV.Null (IV) /TRH group 4.6 ⁇ 0.5 mM;
  • Fig. 9 illustrates the average change in serum glucose levels from baseline.
  • the average change in serum glucose levels from baseline was determined for each time point from 15 to 55 min after administration of methyl-TRH or saline on day 5.
  • the data are presented as mean ⁇ standard deviation. All statistical comparisons were made using the two-tailed Student's t-test.
  • Direct support for the concept that the liver was responsible for the rise in blood glucose came from administration of the AdCMV.mTRH-R vector to rats via the portal vein [a route of administration of an adenovirus vector to rats known to result in limitation of vector gene expression only in hepatocytes (19,20)], followed 5 days later by the administration of intravenous methyl-TRH.
  • the present invention supports the concept that ectopic expression of a non-endogenous naturally occurring receptor can be used to control differentiated functions of cells in vivo, using the natural ligand for the receptor to activate the receptor, and in turn, activate a specific signal transduction pathway in the cell, thus triggering a cell-specific response.
  • the strategy can be used as an alternative means to modulate specific differentiated functions of cells using naturally occurring ligands or receptor-specific drugs and their corresponding receptors not normally relevant to that cell type.
  • the strategy of expressing natural receptors as described herein adds to a growing list of strategies to modify receptor number and/or function, including overexpression of natural receptors in their natural location (21) and "designer" receptors that respond to artificial ligands (22) as means of triggering specific signal transduction pathways to activate specific differentiated functions of cells, and the transfer of normal receptors to their normal location to compensate for mutations in the natural receptor (23,24) .
  • Clinical applications of this strategy include activation of differentiated functions that are impotent and/or dysfunctional secondary to inherited or acquired abnormalities associated with signalling molecules or their specific receptors.
  • a strategy could be used to bypass acquired ligand deficiency states associated with antibodies directed against the ligand, such as observed in individuals with diabetes receiving insulin of human and non-human origin, polyclonal anti-insulin antibodies in individuals with various autoimmune disorders and anti- thyroxine antibodies in patients with immune thyroid disease and plasma cell dyscrasias (1,6,7).
  • receptor-specific autoantibodies intercept the ability of extracellular regulatory molecules to interact with their specific receptors, including the autoantibodies against j ⁇ l-adrenergic receptors implicated in the pathogenesis of idiopathic dilated cardiomyopathy and the cardiomyopathy associated with Chagas' disease, autoantibodies against j ⁇ 2-adrenergic receptors linked to the pathogenesis of some forms of asthma, antibodies to the insulin receptor associated with the diabetes found and type B insulin resistance observed in individuals with acanthosis nigricans and ataxia telangiectasia, autoantibodies to the acetylcholine receptor in myasthenia gravis and to the glutamate receptor in Rasmussen's encephalitis (1,6,7,27,28).
  • this strategy may also be applied to the treatment of diseases for which regulation of a physiologic function in a healthy organ would counterbalance the effects of a disease process.
  • An example of this is suggested by the previous examples, in which blood glucose was elevated by TRH after ectopic expression of TRH-Rs in liver.
  • This approach could be used in a patient with severe hypoglycemia who harbors an inoperable insulin-secreting tumor (insulinoma) in order to maintain normoglycemia over an extended period of time (29) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une cellule in vivo transformée à l'aide d'ADN codant un récepteur de signalisation de cellule, non endogène à celle-ci. Ce récepteur peut activer un processus, endogène à la cellule, de transduction de signal et il peut être activé dans des conditions déterminées, activant ainsi le processus de transduction de signal de manière à réguler une fonction cellulaire commandée par le processus de transduction de signal. Cette invention concerne également un procédé d'expression ectopique d'un récepteur non endogène dans une cellule, ainsi qu'un procédé de régulation d'une fonction cellulaire in vivo, ce dernier consistant à transformer une cellule à l'aide d'ADN codant un récepteur, non endogène à la cellule, de signalisation de cellule, ainsi que décrit ci-dessus, puis, dans des conditions déterminées, à exposer cette cellule à une molécule extracellulaire capable d'activer le récepteur étranger de signalisation de cellule. L'activation du récepteur de signalisation de cellule active le processus de transduction de signal endogène, de manière à réguler une fonction cellulaire commandée par ce processus.
EP96928135A 1995-08-14 1996-08-12 Regulation de fonctions cellulaires a l'aide d'une expression ectopique de recepteurs non endogenes de signalisation de cellule Withdrawn EP0845045A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US225495P 1995-08-14 1995-08-14
US2254 1995-08-14
PCT/US1996/013077 WO1997007233A1 (fr) 1995-08-14 1996-08-12 Regulation de fonctions cellulaires a l'aide d'une expression ectopique de recepteurs non endogenes de signalisation de cellule

Publications (2)

Publication Number Publication Date
EP0845045A1 true EP0845045A1 (fr) 1998-06-03
EP0845045A4 EP0845045A4 (fr) 1999-11-24

Family

ID=21699924

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96928135A Withdrawn EP0845045A4 (fr) 1995-08-14 1996-08-12 Regulation de fonctions cellulaires a l'aide d'une expression ectopique de recepteurs non endogenes de signalisation de cellule

Country Status (5)

Country Link
EP (1) EP0845045A4 (fr)
JP (1) JPH11510704A (fr)
AU (1) AU716407B2 (fr)
CA (1) CA2229287A1 (fr)
WO (1) WO1997007233A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010322A1 (fr) * 1992-10-29 1994-05-11 Board Of Regents, The University Of Texas System Transfert et ciblage du gene recepteur ldl induit par l'adenovirus
WO1994026915A1 (fr) * 1993-05-10 1994-11-24 The Regents Of The University Of Michigan Transfert de genes dans les cellules epitheliales pancreatiques et biliaires
WO1994029447A2 (fr) * 1993-06-09 1994-12-22 Medical Research Council Adn codant le recepteur humain de l'hormone liberant la thyrotrophine
WO1995016772A1 (fr) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Systeme d'expression du gene d'adenovirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
WO1989007136A2 (fr) * 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Hepatocytes modifies et leurs utilisations
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010322A1 (fr) * 1992-10-29 1994-05-11 Board Of Regents, The University Of Texas System Transfert et ciblage du gene recepteur ldl induit par l'adenovirus
WO1994026915A1 (fr) * 1993-05-10 1994-11-24 The Regents Of The University Of Michigan Transfert de genes dans les cellules epitheliales pancreatiques et biliaires
WO1994029447A2 (fr) * 1993-06-09 1994-12-22 Medical Research Council Adn codant le recepteur humain de l'hormone liberant la thyrotrophine
WO1995016772A1 (fr) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Systeme d'expression du gene d'adenovirus

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ATHARI A. & JUNGERMANN K.: "Direct activation by prostaglandin F2a but not thromboxane a2 of glycogenolysis via an increase in inositol 1,4,5-triphosphate in rat hepatocytes." BIOCHEM. BIOPHYS. RES. COMM., vol. 163, no. 3, 29 September 1989 (1989-09-29), pages 1235-1242, XP002105455 *
DIPALMA J.R. ET AL., EDS.: "Basic pharmacology in medicine, 4th ed." 1994 , MEDICAL SURVEILLANCE IN. , WEST CHESTER, PA XP002105459 * Chapter 3: "Receptors and intracellular signals", by S.P. Halenda, p. 28-41 * *
FALCK-PEDERSEN E. ET AL.: "Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin releasing hormone desensitization is cell-specific." MOLECULAR PHARMACOLOGY, vol. 45, no. 4, April 1994 (1994-04), pages 684-689, XP002105449 *
GANDHI C.R. ET AL.: "Endothelin, a potent peptide agonist in the liver." J. BIOL. CHEM., vol. 265, no. 29, 15 October 1990 (1990-10-15), pages 17432-17435, XP002105452 *
GERSHENGORN M.C. ET AL.: "Thyrotropin-releasing hormone (TRH) receptor number determines the size of the TRH-responsive phosphoinositide pool." J. BIOL. CHEM., vol. 269, no. 9, 4 March 1994 (1994-03-04), pages 6779-6783, XP002105450 *
HEINFLINK M. ET AL.: "Thyrotropin-releasing hormone receptor activation does not elevate intracellular cyclic adenosine 3'5'-monophosphate in cells expressing high levels of receptors" J. CLIN. ENDOCRIN. METAB., vol. 79, no. 2, August 1994 (1994-08), pages 650-652, XP002105451 *
MINE T. ET AL.: "Calcium rather than cyclic AMP is an intracellular messenger of parathyroid hormone action on glycogen metabolism in rat hepatocytes." BIOCHEM. J., vol. 258, 15 March 1989 (1989-03-15), pages 889-894, XP002105456 *
See also references of WO9707233A1 *
TOHKIN M. ET AL.: "Mastoparan, a peptide toxin from wasp venom, stimulates glycogenolysis mediated by an increase of the cytosolic Ca++ concentration but not by an increase of cAMP in rat hepatocytes" FEBS LETTERS, vol. 260, no. 2, January 1990 (1990-01), pages 179-182, XP002105454 *
WAKELAM M.J.O. ET AL.: "Activation of two signal-transduction systems in hepatocytes by glucagon." NATURE, vol. 323, no. 4, 4 September 1986 (1986-09-04), pages 68-71, XP002105453 *
WOLFF G. ET AL.: "Ectopic expression of thyrptropin releasing hormone (TRH) receptors in liver modulates organ function to regulate blood glucose by TRH." NATURE GENETICS, vol. 12, no. 3, March 1996 (1996-03), pages 274-279, XP002105457 *

Also Published As

Publication number Publication date
JPH11510704A (ja) 1999-09-21
AU6772196A (en) 1997-03-12
CA2229287A1 (fr) 1997-02-27
AU716407B2 (en) 2000-02-24
WO1997007233A1 (fr) 1997-02-27
EP0845045A4 (fr) 1999-11-24

Similar Documents

Publication Publication Date Title
RU2279441C2 (ru) Выделенный растворимый il-20 рецептор (варианты)
Frevert et al. Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity, and DNA synthesis in 3T3-L1 adipocytes
Fletcher et al. Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity
US5854067A (en) Hexokinase inhibitors
Ruth Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting
KR19980703454A (ko) 바이러스 벡터 및 과다증식성 질환, 특히 재발협착증을치료하기 위한 이의 용도
Joshi et al. Proenkephalin gene expression in C6 rat glioma cells: potentiation of cyclic adenosine 3′, 5′-monophosphate-dependent transcription by glucocorticoids
US5891717A (en) Methods and compositions for inhibiting hexokinase
KR20160032090A (ko) 사이클 아데노신 모노포스페이트-결핍 아데닐일 사이클라아제 및 심부전 치료와 심기능 향상을 위한 조성물 및 방법
US6511811B1 (en) Protein kinase C antagonist related to insulin receptor
Kaiser et al. Evidence that signalling pathways by which thyrotropin-releasing hormone and gonadotropin-releasing hormone act are both common and distinct.
US7083793B2 (en) Tango 243 polypeptides and uses thereof
WO1995013376A1 (fr) Vecteur de therapie genique pour le traitement de l'insuffisance ou des troubles de la production de globules rouges
AU716407B2 (en) Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
US20030073662A1 (en) Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
US6518480B1 (en) Selective target cell activation by expression of a G protein-coupled receptor activated superiorly by synthetic ligand
WO1997007233A9 (fr) Regulation de fonctions cellulaires a l'aide d'une expression ectopique de recepteurs non endogenes de signalisation de cellule
US6677311B1 (en) Inducible HSV-TK in transformed cell populations
AU7869994A (en) Methods of suppressing autoimmune response
JP2000515018A (ja) メラトニン１ａレセプター遺伝子調節領域およびその使用
Wolff et al. Ectopic expression of thyrotropin releasing hormone (TRH) receptors in liver modulates organ function to regulate blood glucose by TRH
Olson et al. Functionally active catalytic domain is essential for guanylyl cyclase-linked receptor mediated inhibition of human aldosterone synthesis
US7432361B2 (en) G protein-coupled receptor, GAVE10
Monnier et al. CRH AND PACAP REGULATE EARLY IMMEDIATE AND NEUROPEPTIDE GENES IN PITUITARY CELLS AND NEURONS.
Seidman et al. Molecular approaches to the study of atrial natriuretic factor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6C 12N 5/10 A, 6C 12P 21/06 B, 6C 12N 5/00 B, 6C 12N 15/00 B, 6C 07K 14/72 B

A4 Supplementary search report drawn up and despatched

Effective date: 19991008

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020610